Key facts
- Eliaz Therapeutics’s last known valuation is $59.4M (Dec 2025).
- It has raised $6.9M across 2 recorded rounds; the latest was Seed Round ($850K) in Mar 2025.
- Notable investors include Impact Assets, National Institute of General Medical Sciences, U.S. Department of Health and Human Services.
- Eliaz Therapeutics has filed 1 Form D with the SEC, most recently Nov 2016 ($2.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Eliaz Therapeutics
Funding rounds
2 roundsAbout Eliaz Therapeutics
Developer of a medical device designed for currently untreatable life-threatening diseases. The company's device targets galectin-3, which is present in patients suffering from diabetes and selectively removes it from the bloodstream and reverses chronic kidney disease, organ fibrosis, and cancer, enabling physicians to provide patients with effective treatment options for AKI/Sepsis and other different inflammatory and fibrotic diseases.
- Sector
- Healthcare
- HQ
- Santa Rosa, CA, United States
- Founded
- 2015
- Employees
- 6
- Website
- eliaztherapeutics.com/
- Ownership
- Privately Held (backing)
Eliaz Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eliaz Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eliaz Therapeutics in its N-PORT filings yet. We sweep new filings monthly.